Drug intelligence / Profile preview

ODC-TARGET D

Development stage: Preclinical
Lead developer: Trutino Biosciences
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ODC-TARGET D is a preclinical-stage antibody-drug conjugate (ADC) developed by Trutino Biosciences for the treatment of solid tumors. The therapeutic candidate utilizes Trutino's proprietary On-Demand Cytokine (ODC) platform, which features a cytokine payload (such as IL-2 or IL-12) that is masked to prevent systemic activity and is specifically activated within the tumor microenvironment. By conjugating this ODC technology to an antibody targeting an undisclosed antigen (referred to as Target D), the drug aims to provide targeted delivery and localized immune activation, potentially improving the therapeutic window compared to systemic cytokine therapies.

Targets

DRD3 (Dopamine receptor D3)

Beyond the preview

Go deeper on ODC-TARGET D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ODC-TARGET D.

Explore the full profile